<DOC>
	<DOCNO>NCT01340196</DOCNO>
	<brief_summary>The objective study evaluate drug-drug interaction potential BI 201335 concomitantly administer tenofovir use treatment regimens HIV infection and/or Hepatitis B infection . Results study serve basis guidance dose adjustment precautionary measure BI201335 tenofovir coadministered .</brief_summary>
	<brief_title>Drug Drug Interaction BI 201335 Tenofovir</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female subject accord medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead electrocardiogram clinical laboratory test ; acceptable finding . 2 . Age =18 =55 year 3 . Weighing least 50 kg , body mass index &gt; =18.5 BMI &lt; =29.9 kg/m2 ( Body Mass Index ) . 4 . Volunteers must leave research unit , entire length study must willing comply protocol complete studyrelated activity . Exclusion criterion : 1 . Any finding medical examination ( include blood pressure , pulse rate electrocardiogram ) deviate normal clinical relevance , assess investigator . 2 . Active disease gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , musculoskeletal , immunologic , rheumatologic , hormonal , neurological system , clinically relevant electrolyte disorder bleed disorder require current medical treatment . 3 . Diseases central nervous system psychiatric disorder . 4 . History photosensitivity recurrent rash . 5 . History orthostatic hypotension , faint spell blackout . 6 . Chronic clinically relevant acute infection . 7 . History allergy/hypersensitivity ( include drug allergy ) deem relevant . 8 . Intake drug long halflife &gt; 24:00 hour within least one month le ten half life respective drug enrollment study ( exception hormonal contraceptive ) . 9 . Use drug might influence result trial 7 day prior enrolment nutraceuticals herbal remedy would interfere either absorption , distribution metabolism BI 201335 NA , prolong QT/QTc interval . 10 . Use investigational drug within 30 day prior enrollment ; plan use investigational drug course current study . 11 . Smoking ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 12 . Inability abstain smoke 3 cigarettes/day period dose study medication . 13 . Drug alcohol abuse ( &gt; 60g/day ) . 14 . Blood donation ( 100 mL within four week prior administration trial ) . 15 . Excessive physical activity within one week prior administration trial . 16 . Any laboratory value outside reference range clinical relevance screening , accord judgment investigator , consultation clinical monitor . 17 . Known elevate liver enzyme past compound ( experimental market ) . 18 . Concomitant administration food product know alter P450 enzyme activity grapefruit juice , Seville oranges , St. John 's Wort . 19 . Concomitant administration oral contraceptive ( subject stop oral contraceptive least 7 day prior Day 1 may include . 20 . Inadequate venous access . 21 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTcF , QTcB interval &gt; 450 m ) . 22 . Infection hepatitis B ( HBV ) , hepatitis C virus ( HCV ) , 23 . Positive test HIV1 HIV2 . For woman child bear potential ( WOCBP ) 24 . Pregnancy plan become pregnant within 2 month study completion 25 . Positive pregnancy test screen visit 26 . No proof sterilization , willing unable consistently use acceptable method double barrier contraception include IUD , diaphragm spermicidal cream/jelly condoms male partner , 3 month completion/termination trial . 27 . Lactation period active breastfeeding time screen 30 day end trial visit . For male subject 28 . No proof sterilization , willing unable consistently use acceptable method double barrier contraception include condom time female partner child bear potential consistently use oral birth control pill , IUD , diaphragm spermicidal cream/jelly ) . Male subject must father child administration first dose 3 month last dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>